{ "id": "thalidomide", "title": "Thalidomide", "lang": "en", "source_lang": "en", "summary": "Thalidomide is an immunomodulatory drug whose severe fetal toxicity transformed medicine regulation and whose later uses include multiple myeloma.", "category": "health", "subcategory": "drugs", "type": "concept", "aliases": [ "α-Phthalimidoglutarimide", "Contergan", "Distaval", "Thalomid" ], "generated_at": "2026-10-22", "model": "pro/gpt-6.1-sol", "url": "https://aiwiki.page/en/thalidomide/", "translations": { "zh-Hans": { "url": "https://aiwiki.page/zh/thalidomide/", "json": "https://aiwiki.page/zh/thalidomide.json" } }, "sections": [ { "heading": "", "text": "Thalidomide is an orally administered drug with immunomodulatory, anti-inflammatory, and antiangiogenic properties. Originally marketed as a sedative and used during pregnancy, it caused severe congenital abnormalities in thousands of children before its dangers became widely recognized in 1961. Its subsequent use in treating erythema nodosum leprosum, an inflammatory complication of leprosy, and multiple myeloma established a markedly different therapeutic role, subject to stringent restrictions intended to prevent fetal exposure. (dailymed.nlm.nih.gov)\n\nThe thalidomide disaster became a turning point in public health, drug regulation, and the evaluation of medicines during pregnancy. The drug also became important to molecular pharmacology: research identified its binding to cereblon, a component of the cellular machinery that controls protein degradation, helping explain both therapeutic effects and developmental toxicity. Its history encompasses chemical stereochemistry, the recognition of drug-induced birth defects, therapeutic repurposing, regulatory reform, and the continuing experiences of people with thalidomide-associated disabilities. (fda.gov)" }, { "heading": "Chemical structure and stereochemistry", "text": "Thalidomide has the molecular formula \\(\\mathrm{C_{13}H_{10}N_{2}O_{4}}\\) and a molar mass of approximately \\(258.2\\ \\mathrm{g\\,mol^{-1}}\\). Its structure joins two cyclic imide systems: a phthalimide group, consisting of a benzene ring fused to a five-membered imide ring, and a six-membered glutarimide ring. The nitrogen of the phthalimide group is bonded to the carbon at position 3 of the glutarimide ring; the two imide systems are therefore linked rather than fused to each other. This carbon is also the molecule’s single stereogenic centre. The compound is described chemically as α-(N-phthalimido)glutarimide. (dailymed.nlm.nih.gov)\n\nThe active substance is a white to off-white, odourless crystalline powder. At \\(25\\,^\\circ\\mathrm{C}\\), it is sparingly soluble in water and ethanol but soluble in dimethyl sulfoxide. These properties describe thalidomide itself, not the entire contents of a commercial dosage form. For example, the United States THALOMID label specifies capsules containing 50, 100, 150 or 200 mg of thalidomide together with pregelatinized starch and magnesium stearate; their gelatin shells contain additional colouring and printing ingredients. The stated capsule strength measures the active ingredient, whereas the formulation also includes these inactive components. (dailymed.nlm.nih.gov)\n\nThe stereogenic carbon gives rise to two enantiomers, designated \\((R)\\)- and \\((S)\\)-thalidomide: non-superimposable mirror-image forms with the same atomic connectivity. For this compound, the forms are respectively dextrorotatory, \\((+)\\), and levorotatory, \\((-)\\). Pharmaceutical thalidomide is supplied as a racemate, an equal mixture whose opposing optical rotations cancel. The distinction is nevertheless biologically relevant: structural and biochemical studies have demonstrated stereoselective binding to the protein cereblon. Racemic composition does not mean that the two configurations are indistinguishable to a biological target. (dailymed.nlm.nih.gov)\n\nThe configurations are not stable in physiological conditions. A 1995 study by T. Eriksson, S. Björkman, B. Roth, A. Fyge and P. Höglund used stereospecific high-performance liquid chromatography to examine separately administered enantiomers and racemic thalidomide in healthy male volunteers. It demonstrated rapid interconversion in humans, with mean modelled inversion rate constants of \\(0.17\\ \\mathrm{h^{-1}}\\) for \\(R\\rightarrow S\\) and \\(0.12\\ \\mathrm{h^{-1}}\\) for \\(S\\rightarrow R\\). In human blood maintained at \\(37\\,^\\circ\\mathrm{C}\\), the corresponding measured values were approximately \\(0.30\\) and \\(0.31\\ \\mathrm{h^{-1}}\\). Thus, administering one configuration did not restrict subsequent exposure to that configuration alone. (pubmed.ncbi.nlm.nih.gov)\n\nChemically, interconversion involves transfer of the hydrogen attached to the stereogenic carbon and rearrangement before that carbon is reprotonated. A 2012 computational study identified pathways involving proton transfer to an adjacent carbonyl oxygen and rotation of the glutarimide ring; water and hydroxide ions lowered the calculated barriers. This chemical lability, together with the human interconversion evidence, makes isolation of an allegedly “safe” enantiomer an unreliable means of avoiding fetal toxicity. Even an initially enantiopure preparation can generate the opposite configuration after administration, so the stereochemical purity of the starting material does not establish the stereochemical composition of exposure in the body. (pubmed.ncbi.nlm.nih.gov)" }, { "heading": "Absorption, disposition, and pharmacokinetics", "text": "Oral thalidomide is absorbed slowly, with peak plasma concentrations generally reached about 2–5 hours after administration. Its poor aqueous solubility limits the rate at which drug becomes available for absorption, particularly at higher doses. Human absolute bioavailability has not been established, although urinary recovery of more than 90% of administered radiolabel indicates substantial absorption. A high-fat meal principally delays absorption: the time to peak concentration increases to approximately 6 hours, while peak concentration and total exposure change by less than 10%. These observations concern the commercial capsule formulation rather than every possible preparation of the substance. (dailymed.nlm.nih.gov)\n\nDose-ranging studies distinguish the rate of absorption from its overall extent. In the healthy-volunteer dataset reviewed by the United States Food and Drug Administration, single doses of 50, 200, and 400 mg produced mean peak concentrations of 0.62, 1.76, and 2.82 micrograms/mL, respectively; corresponding times to peak were 2.9, 3.5, and 4.3 hours. Exposure measured by the area under the plasma concentration–time curve increased approximately proportionally with dose, whereas peak concentrations increased less than proportionally. Thus, larger doses broadened and delayed the concentration profile rather than simply scaling it upwards. The dose-proportionality study, published by Steve K. Teo and colleagues in 2001, also identified possible absorption-limited terminal kinetics, in which slow absorption influences the apparent terminal decline in plasma concentration. (accessdata.fda.gov)\n\nPlasma-protein binding differs between the two enantiomers: geometric mean binding is approximately 55% for \\(R\\)-thalidomide and 66% for \\(S\\)-thalidomide. Distribution is not confined to blood. Teo and colleagues’ 2001 study examined plasma and semen from HIV-seropositive men within a double-blind, placebo-controlled trial; semen was sampled at baseline and at weeks 4 and 8, and thalidomide was detected during oral treatment. This establishes entry into seminal fluid, but does not itself quantify fetal exposure following sexual contact. The associated exposure-control requirements are distinct from these pharmacokinetic observations. (dailymed.nlm.nih.gov)\n\nThalidomide undergoes spontaneous, non-enzymatic hydrolysis, producing ring-opened derivatives; hepatic cytochrome P450-mediated metabolism has only a limited role in its overall disposition. Unchanged thalidomide remains the predominant circulating drug-related component. Laboratory studies reported in the prescribing information found neither inhibition nor induction of human cytochrome P450 enzymes at therapeutic concentrations, distinguishing its disposition from that of drugs cleared predominantly through these enzymes. (ema.europa.eu)\n\nThe plasma elimination half-life is approximately 5–7 hours. In a human study using a single 400-mg radiolabelled dose, 93.6% of administered radioactivity was recovered by day 8, with most excretion occurring within 48 hours. Urine accounted for 91.9% of the dose, principally as hydrolysis products, whereas faecal recovery was below 2%. Less than 3.5% was excreted in urine as unchanged thalidomide: extensive urinary elimination of drug-related material therefore does not imply extensive renal clearance of the parent drug. (dailymed.nlm.nih.gov)" }, { "heading": "Molecular and cellular actions", "text": "Cereblon (CRBN) is the substrate-recognition component of the cullin–RING E3 ubiquitin-ligase complex CRL4–CRBN, which also contains the scaffold CUL4, the adaptor DDB1 and the RING protein RBX1. This machinery helps select proteins for ubiquitin tagging and subsequent destruction by the proteasome. In 2010, Takumi Ito and colleagues identified cereblon as a thalidomide-binding protein, connecting the drug directly to regulated protein turnover. Their experiments linked CRBN-dependent ligase activity to limb outgrowth and fibroblast growth factor Fgf8 expression in zebrafish and chick embryos. The discovery supplied a defined molecular target through which thalidomide could perturb cellular processes, rather than merely a description of its downstream effects. (nature.com)\n\nThalidomide binding changes which substrates cereblon recognizes. Structural studies published in 2014 showed how the drug occupies a pocket in CRBN; subsequent biochemical and cellular experiments established recruitment of additional proteins to the drug-bound ligase. This is a molecular-glue mechanism: a small molecule facilitates an interaction between a substrate and the degradation machinery, allowing substrate ubiquitination and proteasomal destruction. It is therefore more specific than indiscriminate inhibition of protein breakdown. In 2018, Katherine Donovan and colleagues demonstrated thalidomide-dependent degradation of the transcription factor SALL4; loss of CRBN or inhibition of the proteasome prevented this effect. Their comparative experiments also identified different substrate repertoires for thalidomide, lenalidomide and pomalidomide. Shared binding to cereblon consequently does not imply identical substrate selectivity or pharmacological activity. (nature.com)\n\nThalidomide’s effects on cytokines depend on the cell type and experimental or disease context. In 1993, A. L. Moreira and colleagues found that it accelerated degradation of tumour necrosis factor-alpha (TNF-α) messenger RNA in lipopolysaccharide-stimulated human monocytes. At an experimental concentration of 50 micrograms/ml, TNF-α mRNA half-life decreased from approximately 30 to 17 minutes; other measured lipopolysaccharide-induced monocyte cytokines were unaffected. This demonstrated a post-transcriptional mechanism rather than direct neutralization of secreted TNF-α. Clinical observations are not uniform, however: reduced circulating TNF-α has been reported in erythema nodosum leprosum, whereas increases have occurred in HIV-seropositive patients. Thalidomide therefore cannot be characterized simply as a universal suppressor of TNF-α. (pubmed.ncbi.nlm.nih.gov)\n\nIts actions on the immune system likewise include stimulation as well as suppression. Patrick Haslett and colleagues showed in 1998 that thalidomide costimulated primary human T cells already receiving signals through the T-cell receptor, increasing interleukin-2-mediated proliferation and interferon-gamma production, with preferential effects in the CD8-positive subset. In patients with multiple myeloma, treatment has been accompanied by increased circulating natural killer cells and higher plasma interleukin-2 and interferon-gamma. These findings document changes in immune-cell activity, but do not by themselves establish how much each change contributes to tumour control. (pubmed.ncbi.nlm.nih.gov)\n\nThalidomide also inhibits angiogenesis, the formation of new blood vessels. In 1994, Robert D’Amato and colleagues demonstrated inhibition of basic-fibroblast-growth-factor-induced vessel growth in a rabbit corneal micropocket assay. Inhibition has also been observed in a human umbilical artery explant model. Alongside immune-cell and cytokine changes, these vascular effects provide possible routes for modifying the tumour microenvironment rather than acting solely on malignant plasma cells. Nevertheless, activity in an angiogenesis assay is not proof that vascular inhibition explains clinical benefit. The relative contributions of protein degradation, immune modulation and vascular effects to thalidomide’s therapeutic activity remain incompletely established. (pubmed.ncbi.nlm.nih.gov)" }, { "heading": "Early marketing and recognition of the disaster", "text": "Chemie Grünenthal developed thalidomide in West Germany during the 1950s and launched it there as Contergan on 1 October 1957. Sold without prescription, Contergan was promoted as a sleeping aid and sedative; international distribution subsequently expanded through licensing agreements and other trade names. In the United Kingdom, Distillers (Biochemicals) introduced Distaval in April 1958. British promotional material presented it as a non-barbiturate alternative for sleeplessness and emotional or physical stress, emphasizing its supposed safety compared with barbiturates, which were associated with fatal overdoses. Physicians also prescribed it for nausea and vomiting during pregnancy, commonly called morning sickness. (contergan-infoportal.de)\n\nThe early safety claims were not supported by adequate evidence about effects on the developing embryo. The British classification of Distaval as a “new drug of proved value” was an administrative classification affecting prescribing costs and taxation, not the result of independent safety testing. Meanwhile, evidence emerged that repeated use could damage peripheral nerves. On 31 December 1960, the British Medical Journal published Leslie Florence’s letter, “Is Thalidomide to Blame?”, drawing attention to neurological symptoms in patients taking the drug. Further reports followed in 1961. These observations challenged its reputation for harmlessness before the association with congenital abnormalities became publicly established; adult neurological toxicity and fetal developmental injury were distinct safety problems. (nationalarchives.gov.uk)\n\nIn 1961, the German paediatrician and geneticist Widukind Lenz investigated an unusual concentration of infants with limb and ear abnormalities by examining their mothers’ medication histories. In his later account, Lenz dated his first suspicion of thalidomide to 11 November and his telephone warning to Grünenthal to 16 November. Independently, the Australian obstetrician William McBride observed severe congenital abnormalities among babies whose mothers had taken thalidomide. His short communication, “Thalidomide and congenital abnormalities”, appeared in The Lancet on 16 December 1961 and asked whether other clinicians had encountered similar cases. Recognition thus arose from clinical observation and investigation of prenatal exposure, rather than from the drug’s original safety-testing programme. (thalidomide.ca)\n\nWithdrawal occurred through separate national and commercial decisions, not a single worldwide ban. Grünenthal withdrew thalidomide from the West German market on 27 November 1961 and notified its international licensing and distribution partners. British prescribing of Distaval ended with its withdrawal in November 1961, whereas thalidomide remained legally available in Canada until 2 March 1962. McBride’s December publication therefore followed the initial German and British withdrawals, although his observations formed part of the independent recognition of the association. These differing dates distinguish the discovery of the hazard from the subsequent process of removing products from individual markets. (thalidomide-tragedy.com)\n\nIn the United States, the William S. Merrell Company sought authorization in 1960 to market thalidomide as Kevadon. Food and Drug Administration medical reviewer Frances Oldham Kelsey considered the submitted safety evidence insufficient and repeatedly requested additional information despite company pressure. Reports of peripheral nerve injury reinforced her concerns. The application did not become effective, and thalidomide consequently lacked authorization for general commercial marketing during the disaster. Nevertheless, this restriction did not prevent American exposure: an FDA historical account records distribution to more than 1,000 physicians under an investigational programme, through which more than 20,000 people, including pregnant patients, received the drug. The absence of marketing authorization therefore must not be confused with an absence of investigational distribution or fetal exposure. (fda.gov)" }, { "heading": "Embryopathy and developmental toxicity", "text": "Thalidomide embryopathy comprises a spectrum of congenital abnormalities, not simply shortened limbs. Limb-reduction defects include amelia, the complete absence of a limb, and phocomelia, in which absent or severely reduced intervening limb segments leave the hands or feet close to the trunk. Individual bones may be absent or underdeveloped. Other characteristic abnormalities include absent or small external ears, narrow or absent external auditory canals, facial palsy, small or absent eyes, and congenital heart defects. Malformations of the digestive, urinary, and genital systems are also documented. The combination and severity of abnormalities vary; visible limb differences therefore do not describe the full extent of developmental injury. (dailymed.nlm.nih.gov)\n\nExposure timing is especially important during early organ formation. The FDA’s 1998 medical review describes retrospectively reconstructed sensitive periods extending approximately from days 21–36 after conception, with some variation among the historical analyses it assessed. These dates refer to embryonic age, not obstetric gestational age, which is conventionally counted from the last menstrual period and is approximately two weeks greater. The particular structures affected depend on which developmental processes coincide with exposure. Very limited exposure can be sufficient: the prescribing information states that even one capsule, regardless of strength, can cause severe birth defects. This warning describes the possibility of harm, not a claim that every exposed pregnancy has the same outcome. (accessdata.fda.gov)\n\nThe embryopathy is an exposure-induced developmental disorder rather than an inherited genetic disease. A 2002 study by Kerstin Strömland and colleagues examined 64 children born to 34 Swedish parents with thalidomide embryopathy, including 14 mothers and 20 fathers. No malformations or functional abnormalities resembling the characteristic thalidomide pattern were found in their children. This observation distinguishes congenital damage sustained by an exposed embryo from a heritable condition, although the study was a defined cohort rather than an assessment of every survivor’s descendants. (pubmed.ncbi.nlm.nih.gov)\n\nIn 2018, Katherine A. Donovan and colleagues demonstrated that thalidomide promotes cereblon-dependent degradation of SALL4, a developmental transcription factor. Drug binding changes substrate recognition by the cereblon-containing ubiquitin-ligase complex, recruiting SALL4 for ubiquitination and subsequent protein destruction. The finding connected thalidomide exposure to a specific developmental regulator: heterozygous loss-of-function variants in the SALL4 gene cause congenital syndromes, including Duane radial ray syndrome, whose features overlap with thalidomide embryopathy—absent thumbs, limb reduction, eye and ear abnormalities, and congenital heart disease. The resemblance concerns the resulting phenotype; drug-induced protein depletion is not equivalent to inheriting a SALL4 variant. The investigators also found that susceptibility to SALL4 degradation differed between species, with human, other primate, and rabbit SALL4 susceptible, unlike the rodent and fish counterparts examined. Sequence differences in cereblon and SALL4 helped explain these experimental differences. These results established a mechanistic link, not proof that SALL4 loss alone accounts for every manifestation. (elifesciences.org)\n\nHistorical counts require separation of distinct outcomes. The FDA’s 1998 review reported estimates ranging from about 7,000 to more than 10,000 children born with thalidomide-induced abnormalities; these were retrospective estimates, not a complete enumeration of all exposed pregnancies. The prescribing information reports mortality at or shortly after birth of approximately 40% among affected infants. That proportion concerns deaths among infants, not miscarriages or all exposed conceptions. Recognized affected births, fetal losses, infant deaths, and survivors counted at a later date are different—and sometimes overlapping—categories. Consequently, adding them together, or treating a historical birth estimate as a present-day survivor count, produces an unsupported total. (accessdata.fda.gov)" }, { "heading": "Therapeutic repurposing and clinical evidence", "text": "Jacob Sheskin’s reports in 1965 redirected clinical interest toward erythema nodosum leprosum (ENL), an inflammatory complication of leprosy. His October report described ten months of experience in 13 patients and included comparisons with tablets resembling thalidomide but containing placebo. These observations concerned suppression of the inflammatory reaction, not antibacterial treatment of the underlying infection; leprosy itself is treated with multidrug antibacterial therapy. Subsequent controlled investigation included a World Health Organization trial initiated in 1967 at four centres and published in 1971. This double-blind study compared thalidomide with aspirin in male patients with acute reactions, using an active comparator for its analgesic and antipyretic effects, and supported the earlier evidence of symptomatic benefit. (doi.org)\n\nEvidence for activity against multiple myeloma emerged from the study by Seema Singhal and colleagues published in November 1999. Eighty-four previously treated patients with refractory disease received thalidomide alone; 76 had relapsed after high-dose chemotherapy. Response was assessed through reductions in serum or urinary monoclonal protein sustained for at least six weeks. Twenty-seven patients, or 32%, achieved a reduction of at least 25%, including two complete remissions. Among responders, 78% showed the reduction within two months. This demonstrated antitumour activity in heavily pretreated disease, but the single-arm, nonrandomized design could not establish superiority over another treatment or a causal survival benefit. Its 32% response figure also reflected the study’s specified threshold, rather than a directly interchangeable measure across later trials using different response criteria. (nejm.org)\n\nSubsequent randomized controlled trials evaluated thalidomide in combinations and distinguished tumour response from delayed progression and longer survival. In a 207-patient study of newly diagnosed myeloma, thalidomide plus dexamethasone produced responses in 52%, compared with 36% receiving dexamethasone alone. A separate 470-patient placebo-controlled study found median time to progression of 97.7 weeks with the combination versus 28.3 weeks with dexamethasone and placebo. At the reported interim analysis, however, the overall-survival hazard ratio was 0.82, with a 95% confidence interval of 0.57–1.16: the progression advantage did not establish a statistically significant survival advantage at that analysis. (dailymed.nlm.nih.gov)\n\nSurvival evidence also came from combinations with melphalan and prednisone. The IFM 99-06 trial, published in 2007, randomized 447 previously untreated patients aged 65–75 among melphalan–prednisone, the same drugs plus thalidomide, and reduced-intensity autologous stem-cell transplantation. Median overall survival was 51.6 months with the thalidomide-containing combination versus 33.2 months with melphalan–prednisone alone. These results concerned defined regimens and patient populations, rather than demonstrating an equivalent benefit from every thalidomide-containing combination. (pubmed.ncbi.nlm.nih.gov)\n\nLicensed indications differ by jurisdiction. In the United States, thalidomide is indicated with dexamethasone for newly diagnosed multiple myeloma, and separately for acute cutaneous manifestations of moderate-to-severe ENL and maintenance suppression of recurrent cutaneous manifestations. The ENL indication excludes monotherapy when moderate-to-severe neuritis is present. In the European Union, the myeloma indication specifies first-line use with melphalan and prednisone in previously untreated patients aged at least 65 years or ineligible for high-dose chemotherapy. Experimental investigation does not itself expand these authorizations: for example, the European application for thalidomide–dexamethasone induction before high-dose chemotherapy was withdrawn during assessment, leaving that proposed use outside the resulting authorization. (accessdata.fda.gov)" }, { "heading": "Adverse effects beyond fetal toxicity", "text": "Peripheral neuropathy is a potentially severe and irreversible toxicity of thalidomide treatment. It is an acquired injury to peripheral nerves, distinct from neurological abnormalities arising during fetal development. Symptoms include numbness, tingling, and pain in the hands and feet. Neuropathy usually develops after months of treatment, but cases following relatively brief exposure have also been reported; symptoms can appear after treatment has stopped and may resolve slowly or persist permanently. The United States prescribing information describes the relationship with cumulative dose as unclear. In patients treated for erythema nodosum leprosum, attribution is particularly difficult because the underlying disease can itself cause neuropathy, preventing a reliable separation of drug-related and disease-related cases. (dailymed.nlm.nih.gov)\n\nVenous thromboembolism—including deep-vein thrombosis and pulmonary embolism—is especially important in multiple myeloma combination therapy. The United States label reports a controlled trial in which thromboembolic events occurred in 22.5% of patients receiving thalidomide plus dexamethasone, compared with 4.9% receiving dexamethasone alone (\\(p=0.002\\)). These figures describe that trial’s population and regimen, not a universal incidence for thalidomide across indications or combinations. The label also identifies erythropoiesis-stimulating agents and estrogen-containing therapies as concomitant treatments that may increase thromboembolic risk. (dailymed.nlm.nih.gov)\n\nSomnolence reflects thalidomide’s sedative activity and can impair alertness and psychomotor performance. Dizziness, fatigue, and constipation are also prominent adverse effects. In the European Medicines Agency’s safety description for thalidomide combined with melphalan and prednisone, sleepiness, dizziness, constipation, and several neurological symptoms each occur in more than one patient in ten. This frequency category belongs to the specified combination rather than to thalidomide used alone. The same combination commonly produces cytopenias: neutropenia, leukopenia, lymphopenia, anaemia, and thrombocytopenia, denoting reductions in particular white-cell populations, red cells, or platelets. (ema.europa.eu)\n\nBradycardia, or slowing of the heart rate, and syncope have been reported during treatment. Several interactions can reinforce existing toxicities rather than introduce an entirely different adverse effect. Opioids, sedating antihistamines, antipsychotics, anti-anxiety medicines, and alcohol can add to depression of the central nervous system. Medicines that slow cardiac conduction, including beta blockers and digoxin, may augment bradycardia; concurrent neurotoxic medicines can increase the risk of peripheral neuropathy. These overlapping pharmacological effects are identified separately in the product information’s interaction warnings. (medicines.org.uk)\n\nSkin reactions range from rash to severe syndromes reported during postmarketing use, including Stevens–Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS). Their frequency cannot be estimated from the available data in the European product information. They are distinguished from uncomplicated rash by potentially extensive skin injury or systemic involvement and are listed among the clinically important toxicities of thalidomide-containing regimens. Allergic reactions, including angioedema and anaphylaxis, have also been reported. (medicines.org.uk)" }, { "heading": "Restricted distribution and prevention of fetal exposure", "text": "In the United States, THALOMID is available only through its Risk Evaluation and Mitigation Strategy (REMS), which requires certified prescribers and pharmacies, patient enrolment, and compliance with reproductive-risk controls. Counselling and a patient–physician agreement document understanding of fetal toxicity and programme obligations. Patients capable of becoming pregnant must either maintain continuous heterosexual abstinence or use two reliable contraceptive methods from four weeks before treatment until four weeks after discontinuation, including treatment interruptions. These are regulatory conditions of access, not individualized contraceptive recommendations. (dailymed.nlm.nih.gov)\n\nThe United States programme requires two negative pregnancy tests before treatment: one 10–14 days before prescribing and another within the preceding 24 hours. Testing continues weekly during the first month, then every four weeks for regular menstrual cycles or every two weeks for irregular cycles. Because thalidomide is present in semen, male patients must use condoms during sexual contact with partners capable of pregnancy, including after vasectomy, throughout treatment and for four weeks afterward. Sperm donation is prohibited over that interval; all patients are prohibited from donating blood during treatment and for four weeks afterward. (dailymed.nlm.nih.gov)\n\nIn the European Union, Thalidomide BMS received marketing authorization on 16 April 2008 subject to a pregnancy-prevention programme implemented through national arrangements. Educational materials and patient cards support controlled prescribing and dispensing. (ema.europa.eu) The product information requires effective contraception for patients capable of pregnancy from at least four weeks before treatment until at least four weeks afterward, unless continuous abstinence is maintained under the programme. Medically supervised pregnancy testing occurs before treatment, every four weeks during treatment, and four weeks after its end, with an exemption from repeat testing for confirmed tubal sterilization. Prescriptions for this group cover no more than four weeks, and dispensing must occur within seven days of prescription following a negative test. Documented counselling establishes that patients understand both the fetal hazard and the access conditions. (medicines.org.uk)\n\nEuropean precautions also address exposure through semen and donated blood rather than only direct prescribing to pregnant patients. Men whose partners are pregnant, or capable of pregnancy without effective contraception, must use condoms during treatment, interruptions, and for at least seven days after discontinuation, even after vasectomy. Semen or sperm donation is prohibited during treatment and for at least seven days afterward; the same interval applies to blood donation by all patients. The seven-day European post-treatment interval for these precautions differs from the four-week United States requirement. European materials also prohibit sharing capsules and require unused supplies to be returned to a pharmacist. (medicines.org.uk)\n\nLater reports from Brazil distinguish documented maternal exposure from a compatible appearance alone. Lavínia Schüler-Faccini and colleagues reported three new cases of thalidomide embryopathy in 2007, involving children born since 2005. A subsequent dispensing-control study described exposure-associated births in 2005 and 2006, including twins whose mother took capsules prescribed to her own mother for multiple myeloma. (pubmed.ncbi.nlm.nih.gov) By contrast, a 2011 surveillance study identified 109 newborns meeting a screening definition of “thalidomide embryopathy phenotype” among 352,037 births in participating hospitals during 2000–2008: 3.10 per 10,000 births. This was a phenotype-based screening frequency, not the incidence of confirmed drug-induced embryopathy. Detailed assessment during 2007–2008 identified two especially suggestive infants, but neither mother confirmed thalidomide use. Such cases remained suspected rather than established exposure-associated cases, because other causes can produce overlapping limb-reduction abnormalities. (pmc.ncbi.nlm.nih.gov)" }, { "heading": "Effects on drug regulation and research standards", "text": "The thalidomide disaster helped secure United States drug-law reform, but the reform programme preceded recognition of its fetal effects. Senator Estes Kefauver’s hearings on pharmaceutical-industry practices began in 1959, and a bill introduced in 1961 already proposed requirements concerning efficacy, clinical investigations, manufacturing controls, and access to company records. Public attention to thalidomide strengthened support for legislation that President John F. Kennedy signed on October 10, 1962. The Kefauver–Harris amendments required substantial evidence of effectiveness, as well as evidence of safety, before marketing. Effectiveness claims had to rest on adequate, well-controlled investigations rather than testimonials or uncontrolled clinical impressions. The amendments also required affirmative Food and Drug Administration (FDA) approval before a new drug could enter the market, replacing a system under which an application could become effective without an explicit approval decision. (fda.gov)\n\nInvestigational distribution exposed a separate regulatory weakness: although thalidomide lacked United States marketing approval, its sponsor had distributed more than two million tablets for investigational use. The 1962 amendments and implementing regulations strengthened FDA oversight of clinical trials, requiring information about proposed investigations, supporting animal studies, and drug distribution. These provisions made the identity of investigators and the movement of experimental supplies matters of regulatory accountability, rather than leaving investigational distribution largely unchecked. The amendments also introduced a statutory informed-consent requirement, although the original legislation permitted exceptions. This addressed circumstances in which recipients had not been told that a drug was experimental or that its safety remained unestablished; it did not create, in a single step, every element of later research-ethics oversight. (fda.gov)\n\nIn the United Kingdom, the initial response combined expert review with voluntary cooperation rather than immediately establishing compulsory licensing. Following recommendations from a subcommittee chaired by Lord Cohen of Birkenhead, the government established the Committee on Safety of Drugs in 1963, chaired by Sir Derrick Dunlop. Its remit covered the adequacy of toxicity evidence before human investigation, clinical evidence before general release, and collection of subsequently observed adverse effects. The Yellow Card scheme, launched in 1964, supplied a reporting mechanism: Dunlop asked doctors to submit suspected adverse drug reactions. Reports did not require an established causal connection, allowing possible hazards to be collected before definitive proof existed. This became an institutional mechanism for postmarketing safety surveillance, distinct from premarketing assessment. (api.parliament.uk)\n\nThe Medicines Act 1968 subsequently provided a statutory framework for controlling medicinal products; its licensing provisions came into operation on September 1, 1971. Section 19 specified safety, efficacy for the proposed uses, and pharmaceutical quality—including manufacturing methods and arrangements for maintaining quality—as considerations in product-licence decisions. The transition therefore involved more than expanding adverse-reaction reporting: it replaced reliance on voluntary scrutiny with legally enforceable licensing arrangements. The 1968 parliamentary debate explicitly connected the proposed licensing system with the earlier voluntary response to thalidomide. (legislation.gov.uk)\n\nThalidomide also demonstrated why reproductive safety cannot be inferred simply from tolerability in adults or from negative results in one animal species. Developmental assessment must consider the experimental model, exposure, and developmental stage. Later mechanistic evidence clarified one limitation of cross-species extrapolation: studies published in 2018 found thalidomide-dependent degradation of the developmental transcription factor SALL4 in susceptible species, whereas sequence differences protected mouse SALL4 from that response. Even mice engineered to express human cereblon did not thereby reproduce thalidomide’s developmental toxicity. Modern reproductive-toxicity frameworks consequently address model selection, exposure margins, study design, and interpretation of risk rather than treating an animal result as a direct guarantee of human safety. (pubmed.ncbi.nlm.nih.gov)" }, { "heading": "Survivors, disability, and compensation", "text": "Congenital limb differences and damage to hearing or vision have lifelong consequences, but survivors’ functional abilities and support needs vary considerably. Ageing can add pain and reduced mobility to impairments accommodated for decades. A 2015 survey of 351 survivors in the United Kingdom, published by Elizabeth Newbronner and colleagues in 2019, documented substantial secondary musculoskeletal problems: 49% reported generalised pain, including 26% who described it as severe or continuous. Approximately two-fifths were unable to work because of health problems. These were self-reported findings from a survivor population, not estimates for everyone exposed prenatally. Physical health-related quality of life was substantially below population norms, whereas average mental health-related scores were only marginally lower; 40.9% scored above the general-population average on the latter measure. Physical impairment therefore did not provide a complete account of individual wellbeing. (pubmed.ncbi.nlm.nih.gov)\n\nSupport encompasses rehabilitation, assistive equipment, accessible housing, transport and personal assistance rather than a single standard programme. The British government’s 2012 health-grant announcement specifically identified adapted homes and cars, and recognised increasing health needs with age. The Thalidomide Trust’s wheelchair information describes access through local wheelchair services and occupational-therapy referral, illustrating how equipment provision also depends on navigating services. Sensory differences create additional access requirements: the Trust’s National Advisory Council documented that hearing or communication difficulties could complicate telephone or video disability-benefit assessments. These barriers are distinct from the anatomical severity of a survivor’s original injuries. (gov.uk)\n\nBritish compensation campaigns developed alongside family-organised support. Parents established the Thalidomide Society in 1962, incorporating it in 1963; its early work included mutual support and fundraising coordinated with the Lady Hoare appeal. Litigation against Distillers, the British distributor, produced an initial settlement in 1968. Wider public pressure followed, notably The Sunday Times article of 24 September 1972, which criticised the proposed compensation and appealed for a more generous offer. The ensuing publication restrictions became the subject of The Sunday Times v. the United Kingdom, decided by the European Court of Human Rights in 1979. That judgment concerned freedom of expression, not a determination of Distillers’ liability for the injuries. (thalidomidesociety.org)\n\nThe expanded 1973 settlement established the financial arrangements underlying the Thalidomide Children’s Trust, subsequently known as the Thalidomide Trust. Its declaration of trust was dated 10 August 1973. The arrangement combined individual compensation with funds held for longer-term support. Court approval of a negotiated settlement should not be conflated with a contested judgment establishing negligence: contemporary reporting recorded that Distillers continued to deny negligence when the settlement was approved. The Trust’s subsequent charitable functions include grants to individuals, services, advocacy and research. (wellcomecollection.org)\n\nGovernment health grants constituted a separate funding stream from company-funded compensation. On 20 December 2012, Care and Support Minister Norman Lamb announced approximately £80 million over ten years for survivors in England, administered through the Trust after a three-year pilot. The announcement identified 325 intended beneficiaries in England and explicitly distinguished arrangements in the devolved administrations. In March 2021, the government committed to continuing the English Thalidomide Health Grant for beneficiaries’ lifetimes beyond the existing funding period ending in 2023. Wales announced its own lifetime commitment in September 2022, with regular reviews taking account of beneficiary numbers and underlying needs. (gov.uk)" }, { "heading": "Related drugs and continuing research", "text": "Lenalidomide and pomalidomide are structurally related immunomodulatory drugs, but they are not interchangeable versions of thalidomide. Their shared ability to bind cereblon does not confer identical substrate selectivity, potency, indications, or adverse-effect profiles. For example, United States labeling includes lenalidomide for maintenance treatment after autologous stem-cell transplantation in multiple myeloma and for specified myelodysplastic syndromes with a chromosome 5q deletion. Pomalidomide has a myeloma indication after at least two prior therapies, including lenalidomide and a proteasome inhibitor, under defined progression criteria, and a separate indication for specified patients with Kaposi sarcoma. Both retain boxed warnings for embryo-fetal toxicity and thromboembolism; lenalidomide also has a boxed warning for hematological toxicity. Structural modification therefore does not establish reproductive safety. (dailymed.nlm.nih.gov)\n\nDifferences in drug-induced molecular recognition help explain the distinct biological activities of these compounds. In work published in 2014, Jan Krönke and colleagues demonstrated that lenalidomide promotes cereblon-dependent destruction of the transcription factors IKZF1 and IKZF3, also called Ikaros and Aiolos, in myeloma cells. Their 2015 research identified casein kinase 1α, encoded by CSNK1A1, as another lenalidomide-dependent substrate. Cells with a chromosome 5q deletion already have reduced CSNK1A1 gene dosage, creating a vulnerability to further depletion of its protein product. Separately, a 2018 comparison in human embryonic stem cells found different degradation profiles for thalidomide, lenalidomide, and pomalidomide, including additional proteins reduced by pomalidomide. These findings make potency a substrate- and assay-specific property rather than a single ranking applicable to every effect. (pubmed.ncbi.nlm.nih.gov)\n\nThis research helped establish targeted protein degradation as a drug-discovery strategy. Thalidomide-related molecular glues alter the surface through which cereblon recognizes proteins, enabling recruitment of endogenous substrates that are subsequently ubiquitinated and degraded. The drug need not contain a separate ligand designed to bind each recruited protein. This differs from bifunctional proteolysis-targeting chimeras, or PROTACs, which join an independently selected target-binding ligand to a ubiquitin-ligase-binding ligand through a chemical linker. In 2015, Georg Winter and colleagues demonstrated this engineered approach with dBET1: conjugating a cereblon-binding thalidomide derivative to the BET-bromodomain ligand JQ1 produced cereblon-dependent degradation of BET proteins. Thus, drug-induced recruitment of existing cellular proteins and deliberately constructed two-ligand degraders exploit related machinery but have different molecular architectures. (elifesciences.org)\n\nDevelopmental research addresses which recruited proteins account for vulnerability in particular tissues and developmental periods. SALL4 degradation provides one experimentally supported mechanism, but additional substrates have been identified. In 2019, Tomoko Asatsuma-Okumura and colleagues showed that thalidomide induces degradation of p63 isoforms; zebrafish experiments connected depletion of different isoforms with pectoral-fin and otic-vesicle abnormalities. These findings do not establish that p63 explains every corresponding human malformation. Species differences also involve both cereblon and its potential substrates: the 2018 SALL4 study found that introducing human cereblon into mouse cells was insufficient to make mouse SALL4 susceptible to degradation, whereas replacing five amino acids in its relevant zinc-finger domain enabled degradation in a human-cell system. (pubmed.ncbi.nlm.nih.gov)\n\nHuman-cell models allow these mechanisms to be tested without assuming that animal susceptibility transfers directly to humans. In 2020, David Belair and colleagues used human induced pluripotent stem cells differentiating into lateral plate mesoderm, a developmental lineage contributing to limb formation. Thalidomide, lenalidomide, and pomalidomide reduced SALL4 and inhibited differentiation; an engineered degradation-resistant SALL4 variant, G416A, protected this assay endpoint from all three compounds. Such experiments establish a causal contribution within the tested cellular system, not a complete reconstruction of human embryopathy. The model was developed as a potential screen for analogues that retain SALL4-degrading activity and as a means of separating disruption of particular differentiation pathways from nonspecific cellular toxicity. (nature.com)" } ], "links": [ "pregnancy", "multiple-myeloma", "public-health", "pharmacology", "molar-mass", "enantiomer", "protein", "pharmacokinetics", "hydrolysis", "metabolism", "half-life", "transcription-factor", "cytokine", "immune-system", "t-cell", "plasma-cell", "united-kingdom", "nausea", "united-states", "clinical-trial", "phenotype", "species", "world-health-organization", "chemotherapy", "randomized-controlled-trial", "prednisone", "european-union", "thrombosis", "dizziness", "constipation", "central-nervous-system", "rash", "brazil", "public-health-surveillance", "informed-consent", "quality-of-life", "rehabilitation", "molecular-recognition" ], "sources": [ { "title": "DailyMed — THALOMID- thalidomide capsule", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061" }, { "title": "Structural basis of thalidomide enantiomer binding to cereblon", "url": "https://www.nature.com/articles/s41598-018-19202-7" }, { "title": "Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide", "url": "https://pubmed.ncbi.nlm.nih.gov/7702998/" }, { "title": "Enantiomerization mechanism of thalidomide and the role of water and hydroxide ions", "url": "https://pubmed.ncbi.nlm.nih.gov/23065668/" }, { "title": "Thalidomide clinical pharmacology review, NDA 20-785", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_Thalidomide_ClinPharmR.pdf" }, { "title": "Thalidomide dose proportionality assessment following single doses to healthy subjects", "url": "https://pubmed.ncbi.nlm.nih.gov/11402635/" }, { "title": "Thalidomide is distributed into human semen after oral dosing", "url": "https://pubmed.ncbi.nlm.nih.gov/11560881/" }, { "title": "Thalidomide Pharmion: European public assessment report", "url": "https://www.ema.europa.eu/en/documents/assessment-report/thalidomide-celgene-epar-public-assessment-report_en.pdf" }, { "title": "Identification of a primary target of thalidomide teratogenicity", "url": "https://pubmed.ncbi.nlm.nih.gov/20223979/?dopt=Abstract" }, { "title": "Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide", "url": "https://www.nature.com/articles/nature13527" }, { "title": "Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation", "url": "https://pubmed.ncbi.nlm.nih.gov/8496685/" }, { "title": "Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset", "url": "https://pubmed.ncbi.nlm.nih.gov/9607928/" }, { "title": "Thalidomide is an inhibitor of angiogenesis", "url": "https://pubmed.ncbi.nlm.nih.gov/7513432/" }, { "title": "Conterganskandal: Zeitstrahl mit Meilensteinen", "url": "https://contergan-infoportal.de/stiftung/historie" }, { "title": "Thalidomide and society - The National Archives", "url": "https://www.nationalarchives.gov.uk/explore-the-collection/explore-by-topic/health-and-welfare/thalidomide-and-society/" }, { "title": "The History of Thalidomide", "url": "https://www.thalidomide.ca/wp-content/uploads/2017/12/Dr-Lenz-history-of-thalidomide-1992.pdf" }, { "title": "McBride WG (1961) - The James Lind Library", "url": "https://www.jameslindlibrary.org/mcbride-wg-1961/" }, { "title": "Thalidomide and Congenital Abnormalities", "url": "https://www.avite.org/wp-content/uploads/1960/12/19611216-Carta-a-Lancet-Alerta-20-malformac-asoc-talidomida.McBride.pdf" }, { "title": "Frequently Asked Questions (FAQ)", "url": "https://www.thalidomide-tragedy.com/faq" }, { "title": "Question Period Notes", "url": "https://search.open.canada.ca/qpnotes/record/hc-sc%2CMH-2022-QP-0060" }, { "title": "A Brief History of the Center for Drug Evaluation and Research", "url": "https://www.fda.gov/about-fda/fda-history-exhibits/brief-history-center-drug-evaluation-and-research" }, { "title": "Thalidomide medical review, 1998", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_Thalidomide_MedR.pdf" }, { "title": "Offspring of male and female parents with thalidomide embryopathy: birth defects and functional anomalies", "url": "https://pubmed.ncbi.nlm.nih.gov/12210472/" }, { "title": "Further Observation with Thalidomide in Lepra Reactions", "url": "https://doi.org/10.5935/0305-7518.19650036" }, { "title": "Leprosy", "url": "https://www.who.int/en/news-room/fact-sheets/detail/leprosy" }, { "title": "WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients", "url": "https://pubmed.ncbi.nlm.nih.gov/4947831/" }, { "title": "DailyMed - THALOMID- thalidomide capsule", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061" }, { "title": "Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial", "url": "https://pubmed.ncbi.nlm.nih.gov/17920916/" }, { "title": "THALOMID prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020785s074lbl.pdf" }, { "title": "Thalidomide BMS (previously Thalidomide Celgene)", "url": "https://www.ema.europa.eu/nl/medicines/human/EPAR/thalidomide-bms" }, { "title": "Thalidomide BMS (previously Thalidomide Celgene) — European Medicines Agency", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-bms" }, { "title": "Thalidomide BMS 50 mg Hard Capsules — Summary of Product Characteristics", "url": "https://www.medicines.org.uk/emc/product/6317/smpc" }, { "title": "New cases of thalidomide embryopathy in Brazil", "url": "https://pubmed.ncbi.nlm.nih.gov/17676592/" }, { "title": "Clinical use and control of the dispensing of thalidomide in Brasilia-Federal District, Brazil, from 2001 to 2012", "url": "https://new.scielo.br/j/csc/a/jm9qHnHsHqWQ9RqkhLHBshN/?ilang=en&lang=en" }, { "title": "Epidemiological Surveillance of Birth Defects Compatible with Thalidomide Embryopathy in Brazil", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3130769/" }, { "title": "Promoting Safe & Effective Drugs for 100 Years", "url": "https://www.fda.gov/about-fda/histories-product-regulation/promoting-safe-effective-drugs-100-years?trk=article-ssr-frontend-pulse_little-text-block" }, { "title": "FDA and Clinical Drug Trials: A Short History", "url": "https://www.fda.gov/media/110437/download?attachment=" }, { "title": "Protection of Human Subjects; Informed Consent; Proposed Rule", "url": "https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/protection-human-subjects-informed-consent-proposed-rule" }, { "title": "Drugs (Sub-Committee's Report) (Hansard, 4 April 1963)", "url": "https://api.parliament.uk/historic-hansard/written-answers/1963/apr/04/drugs-sub-committees-report" }, { "title": "Withdrawn] The UK: your partner for patient safety", "url": "https://www.gov.uk/government/publications/the-uk-your-partner-for-patient-safety/the-uk-your-partner-for-patient-safety" }, { "title": "Human Medicines", "url": "https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/539067/2905556_HMRA_Annual_Report_Accessible_v0.2.pdf" }, { "title": "Commission on Human Medicines Annual Report 2014", "url": "https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/580497/2014_annual_report.pdf" }, { "title": "Medicines Act 1968", "url": "https://www.legislation.gov.uk/ukpga/1968/67/body/made" }, { "title": "Previous legislation in force before August 2012", "url": "https://assets.publishing.service.gov.uk/media/6012d7f2d3bf7f05b92f6cfc/BG_2020_Brexit_Final_version.pdf" }, { "title": "Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome", "url": "https://pubmed.ncbi.nlm.nih.gov/30067223/" }, { "title": "The health and quality of life of Thalidomide survivors as they age – Evidence from a UK survey", "url": "https://pubmed.ncbi.nlm.nih.gov/30650111/" }, { "title": "The health and quality of life of Thalidomide survivors as they age – Evidence from a UK survey", "url": "https://journals.plos.org/plosone/article/file?id=10.1371%2Fjournal.pone.0210222&type=printable" }, { "title": "Health grant awarded to victims of Thalidomide", "url": "https://www.gov.uk/government/news/health-grant-awarded-to-victims-of-thalidomide" }, { "title": "About Us – Thalidomide Society", "url": "https://thalidomidesociety.org/about-us/" }, { "title": "The Sunday Times v. the United Kingdom – 6538/74 [1979] ECHR 1", "url": "https://www.bailii.org/eu/cases/ECHR/1979/1.html" }, { "title": "Declaration of Trust, 10 August 1973", "url": "https://wellcomecollection.org/works/xp7232u8" }, { "title": "The Thalidomide Trust – 266220", "url": "https://register-of-charities.charitycommission.gov.uk/en/charity-search/-/charity-details/266220/full-print" }, { "title": "Budget 2021 (HTML)", "url": "https://www.gov.uk/government/publications/budget-2021-documents/budget-2021-html" }, { "title": "Written Statement: Thalidomide Trust Health Grant Funding (29 September 2022)", "url": "https://www.gov.wales/written-statement-thalidomide-trust-health-grant-funding" }, { "title": "DailyMed - REVLIMID- lenalidomide capsule", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be" }, { "title": "DailyMed - POMALYST- pomalidomide capsule", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66" }, { "title": "Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells", "url": "https://pubmed.ncbi.nlm.nih.gov/24292625/" }, { "title": "Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4853910/" }, { "title": "Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6156078/" }, { "title": "Selective Target Protein Degradation via Phthalimide Conjugation", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4937790/" }, { "title": "p63 is a cereblon substrate involved in thalidomide teratogenicity", "url": "https://pubmed.ncbi.nlm.nih.gov/31591562/" }, { "title": "Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4", "url": "https://www.nature.com/articles/s41598-020-59542-x" }, { "title": "Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7046148/" } ], "license": "https://creativecommons.org/licenses/by/4.0/" }